Background: Deep brain stimulation (DBS) has been used for treatment of advanced Parkinson's disease (PD) since 1990's. Duodenal levodopa infusion (DLI) has been available since 2006.
Materials And Methods: Patient records of DLI patients and clinical data of DBS patients from 2006-2010 were requested from all university and central hospitals in Finland.
Results: DLI was tested on 105 patients. 84 had a favourable response and were on long-term treatment. 85 patients underwent DBS operation. Technical problems and complications were common in DLI treated patients.
Conclusions: DLI has become as popular as DBS in the treatment of advanced PD, but has a quite high complication rate.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Comparison of Efficacy and Safety of Device-Based Interventions Versus Pharmacological Therapy in the Management of Patients With Advanced Parkinson's Disease: A Literature Review.
Cureus
December 2024
College of Medicine, Almaarefa University, Riyadh, SAU.
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by motor and non-motor symptoms that profoundly impact patients' quality of life. While pharmacological therapies such as levodopa remain the mainstay of treatment, their long-term use is often limited by motor complications. Device-based interventions, including deep brain stimulation (DBS) and continuous dopaminergic infusions, have emerged as alternatives, promising sustained symptomatic control and reduced medication-related side effects.
View Article and Find Full Text PDFVyalev - foscarbidopa/foslevodopa subcutaneous infusion for Parkinson's disease.
Med Lett Drugs Ther
January 2025
Long-term effect and reasons for switching and combining device-aided therapies in Parkinson's Disease.
Neurol Neurochir Pol
January 2025
Department of Neurology, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Introduction: In the advanced stages of Parkinson's disease (PD), when standard drug adjustments fail to sufficiently improve patients' quality of life, device-aided therapies (DATs) such as deep brain stimulation (DBS), continuous subcutaneous apomorphine infusion (CSAI), levodopa-carbidopa intestinal gel infusion (LCIG), levodopa-carbidopa-entacapone intestinal gel infusion, or continuous subcutaneous foslevodoa-foscarbidopa infusion are beneficial in the long run. However, sometimes patients need to switch or combine DATs due to either adverse events or loss of efficacy.
Aim Of Study: The aim of this article was to summarise the existing data on the long-term efficacy and adverse events of DATs, and to review the data on the rationale and efficacy for switching or combining DATs in advanced PD.
Use of the MNCD Classification to Monitor Clinical Stage and Response to Levodopa-Entacapone-Carbidopa Intestinal Gel Infusion in Advanced Parkinson's Disease.
Brain Sci
December 2024
Hospital Infanta Sofía, San Sebastián de los Reyes, 28702 Madrid, Spain.
Background And Objective: Staging Parkinson's disease (PD) with a novel simple classification called MNCD, based on four axes (Motor; Non-motor; Cognition; Dependency) and five stages, correlated with disease severity, patients' quality of life and caregivers' strain and burden. Our aim was to apply the MNCD classification in advanced PD patients treated with device-aided therapy (DAT).
Patients And Methods: A multicenter observational retrospective study of the first patients to start the levodopa-entacapone-carbidopa intestinal gel (LECIG) in Spain was performed (LECIPARK study).
How well is the female population represented in clinical trials with infusion therapies for Parkinson's disease? A systematic review and metanalysis.
Eur J Neurol
January 2025
Parkinson and Movement Disorders Unit, Study Center for Neurodegenerative diseases (CESNE), Department of Neuroscience, Padua Neuroscience Center (PNC), University of Padua, Padua, Italy.
Background: Parkinson's disease (PD) is a neurodegenerative disorder affecting both sexes, but differences exist between male and female in clinical manifestations, functional impact of symptoms and hormonal influences. Therefore, representativeness of females in PD trials indirectly determines the external validity of the clinical research in this field.
Objective: To estimate the representativeness of female in infusion therapy trials for advanced PD.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!